search
Back to results

Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis

Primary Purpose

Osteo Arthritis Knee

Status
Completed
Phase
Phase 2
Locations
Egypt
Study Type
Interventional
Intervention
allogenic lyophilized growth factors
Sponsored by
Rasmia Elgohary
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteo Arthritis Knee focused on measuring osteoarthritis, allogenic platelet rich plasma, lyophilization, growth factors

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria

  • Clinical and radiographic diagnosis of primary knee osteoarthritis
  • Patients must be symptomatic

Exclusion Criteria:

  • Patients with secondary knee osteoarthritis
  • previous intra-articular steroid, or hyaluronic knee injection in last year
  • Patients with other disabling lower limb osteoarthropathy or myopathy

Sites / Locations

  • rheumatology and clinical immunology unit of internal medicine department of Kasr Al-ainy Hospital, Cairo University

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Allogenic lyophilized growth factors

Standard of care

Arm Description

Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.

The patients were kept on their traditional medications without any intervention

Outcomes

Primary Outcome Measures

Change from Baseline WOMAC scores at 6 months
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores consist of 24 questions in 3 sections regarding; five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). A sum of the scores for all three sub-scales gives a total WOMAC score. The higher scores mean a worse outcome.
Change from Baseline structural outcomes scores at 6 months
Knee ultrasonography assessment of effusion, femoral cartilage, anterior horn medial meniscus, synovial hypertrophy

Secondary Outcome Measures

post injection complications of the intervention treatment
The patients of the intervention group were asked if they experienced any adverse events following the injection, with special concern on: Post-injection pain: Both the duration and intensity were documented. The pain intensity was measured by 0-10 visual analogue scale (VAS). General symptoms or signs related to infection and allergy such as fever, chills, pruritus, dyspnea, urticaria, or rash. Erythema, swelling, or abnormal discharge from the site of injection.

Full Information

First Posted
March 27, 2020
Last Updated
January 26, 2021
Sponsor
Rasmia Elgohary
search

1. Study Identification

Unique Protocol Identification Number
NCT04331327
Brief Title
Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis
Official Title
Clinical and Ultrasonographic Assessment of Effectiveness of Intra-articular Knee Injection Using Platelet Derived Lyophilized Growth Factors in Egyptian Patients With Symptomatic Primary Knee Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
April 28, 2018 (Actual)
Study Completion Date
April 28, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Rasmia Elgohary

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
the study was conducted on 31-patients with symptomatic primary knee osteoarthritis. The patients were randomized into intervention and control groups. The control group was kept on their medications without intervention. The intervention group received two doses of allogenic lyophilized growth factors (L-GFs); at baseline and after 2 months.
Detailed Description
the study included 31 patients with symptomatic primary knee osteoarthritis (KOA) The study group was randomized into an intervention group and a control one. The control group patients were kept on their traditional medications without any intervention, while intervention group patients were instructed to stop using non-steroidal anti-inflammatory drugs (NSAID) at least 1 week before the assessment and throughout the study. All participants were subjected to baseline clinical, radiographic, and ultrasonography assessment. Follow up assessments was conducted after 6 months. Patients of the intervention group received two doses of intra-articular knee injections of allogenic lyophilized growth factors (L-GFs); one dose at the baseline and the other was after 2 months. Lyophilized GFs were prepared at the Cairo Medical Centre Blood Bank from allogenic platelet rich plasma to according a previously published patented method. Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration. The injection was done under complete guidance of ultrasonography through lateral supra-patellar short axis in-plane approach under sterile aseptic conditions. After injection, local ice application and oral paracetamol were allowed if the patient felt pain. NSAIDs were completely avoided as they may inhibit the desired post-injection inflammatory process. Patients were encouraged to restrict vigorous knee activities for 48 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteo Arthritis Knee
Keywords
osteoarthritis, allogenic platelet rich plasma, lyophilization, growth factors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Allogenic lyophilized growth factors
Arm Type
Active Comparator
Arm Description
Two doses of intra-articular knee injections of lyophilized growth factors were received one dose at the baseline and the other was after 2 months.
Arm Title
Standard of care
Arm Type
No Intervention
Arm Description
The patients were kept on their traditional medications without any intervention
Intervention Type
Drug
Intervention Name(s)
allogenic lyophilized growth factors
Intervention Description
Prior to usage, reconstitution of the product was done using 1-ml saline and 1-ml lignocaine followed by gentle vial rubbing for 3 minutes. Then, the mixture was kept at ambient temperature for 5 minutes to ensure complete protein re-hydration.
Primary Outcome Measure Information:
Title
Change from Baseline WOMAC scores at 6 months
Description
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores consist of 24 questions in 3 sections regarding; five items for pain (score range 0-20), two for stiffness (score range 0-8), and 17 for functional limitation (score range 0-68). A sum of the scores for all three sub-scales gives a total WOMAC score. The higher scores mean a worse outcome.
Time Frame
At baseline and after 6 months.
Title
Change from Baseline structural outcomes scores at 6 months
Description
Knee ultrasonography assessment of effusion, femoral cartilage, anterior horn medial meniscus, synovial hypertrophy
Time Frame
At baseline and after 6 months.
Secondary Outcome Measure Information:
Title
post injection complications of the intervention treatment
Description
The patients of the intervention group were asked if they experienced any adverse events following the injection, with special concern on: Post-injection pain: Both the duration and intensity were documented. The pain intensity was measured by 0-10 visual analogue scale (VAS). General symptoms or signs related to infection and allergy such as fever, chills, pruritus, dyspnea, urticaria, or rash. Erythema, swelling, or abnormal discharge from the site of injection.
Time Frame
at each time following the injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria Clinical and radiographic diagnosis of primary knee osteoarthritis Patients must be symptomatic Exclusion Criteria: Patients with secondary knee osteoarthritis previous intra-articular steroid, or hyaluronic knee injection in last year Patients with other disabling lower limb osteoarthropathy or myopathy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamel Gado, MD
Organizational Affiliation
Kasr Alainy School of Medicine, Cairo University
Official's Role
Principal Investigator
Facility Information:
Facility Name
rheumatology and clinical immunology unit of internal medicine department of Kasr Al-ainy Hospital, Cairo University
City
Cairo
ZIP/Postal Code
11562
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
study protocol and statistical analysis plan
IPD Sharing Time Frame
after publication
Citations:
PubMed Identifier
33754800
Citation
El-Gohary R, Diab A, El-Gendy H, Fahmy H, Gado KH. Using intra-articular allogenic lyophilized growth factors in primary knee osteoarthritis: a randomized pilot study. Regen Med. 2021 Feb;16(2):113-115. doi: 10.2217/rme-2020-0104. Epub 2021 Mar 23.
Results Reference
derived
Links:
URL
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2018091713
Description
A patent method describing the preparation of lyophilized growth factors from allogenic platelet rich plasma

Learn more about this trial

Intra-articular Injection of Allogenic Lyophilized Growth Factors in Primary Knee Osteoarthritis

We'll reach out to this number within 24 hrs